Targeted therapies in systemic lupus erythematosus: Successes, failures and future

Annals of the Rheumatic Diseases

Volumn 70, Issue SUPPL. 1, 2011, Pages

  Hahn, Bevra H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORIGERIMOD; GAMMA INTERFERON; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; TOCILIZUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONFERENCE PAPER; DIARRHEA; DISEASE ACTIVITY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MONOCYTE MACROPHAGE PRECURSOR CELL; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ADAPTIVE IMMUNITY; DRUG TREATMENT FAILURE; INNATE IMMUNITY; INTERVENTION STUDY; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; PROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79953002735     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.142208     Document Type: Conference Paper

References (25)

1. Nikpour M, Urowitz MB, Ibañez D, et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.
2. Marshak-Rothstein A, Ohashi PS. Intricate connections between innate and adaptive autoimmunity. Curr Opin Immunol 2007;19:603-5. (Pubitemid 50014681)
3. Schiffer L, Bethunaickan R, Ramanujam M, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008;180:1938-47.
4. McCune WJ, Marder W, Riskalla M. Immunosuppressive drug therapy. In: Wallace D, Hahn BH, eds. Dubois lupus erythematosus. Philadelphia, PA: Lippincott, Williams and Wilkens, 2007:1198-224.
5. Appel GB, Contreras G, Dooley MA, et al.; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
6. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128-40.
7. Ginzler EM, Wofsy D, Isenberg D, et al.; ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010;62:211-21.
8. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
9. Ginzler EM, Appel BG, Dooley MA, et al. Aspreva Lupus Management Study (ALMS): maintenance results. Arthritis Rheum 2010;62:S871 (abstract).
10. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010;43:84-97.
11. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13:391-7. (Pubitemid 38788502)
12. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87.
13. Immupharma announces final results of phase IIb study of LUPUZOR™ in lupus. Online announcement, Immupharma PLC, London, 19 November 2009.
14. Cardiel MH, Tumlin JA, Furie RA, et al.; LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum 2008;58:2470-80.
15. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab Registry. Arthritis Rheum 2010;62:2458-66.
16. Jónsdóttir T, Gunnarsson I, Mourão AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 2010;49:1502-4.
17. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
18. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
19. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, place-bocontrolled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2009;62:580-1.
20. Petri M, Levy RA, Merrill JT, et al. Belimumab, a BlyS-specific inhibitor reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum 2010;62:S190 (abstract).
21. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
22. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4.
23. Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:173-86;x.
24. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.
25. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52.